MDXG Q2 2022 Earnings — MiMedx Group, Inc. Revenue & Financial Results | Market Cap Arena

MDXGMiMedx Group, Inc.

$684M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$67M-1.9% YoY

Gross Profit

$55M82.3% margin

Operating Income

-$10M-14.4% margin

Net Income

-$11M-16.2% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

+13.6%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$169M

Total Liabilities

$90M

Stockholders' Equity

$79M

Cash & Equivalents

$73M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$67M	$68M	-1.9%
Gross Profit	$55M	$55M	-0.6%
Operating Income	-$10M	-$410,000	-2250.2%
Net Income	-$11M	-$2M	-510.9%

Revenue Segments

Health Care

$66M50%

Advanced Wound Care, Tissue And Other

$60M45%

Advanced Wound Care, Umbilical Cord-Derived

$6M4%

Section 351

$600,0000%

Product and Service, Other

$78,0000%